Targeted combo for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of targeted therapy drugs for people with advanced colorectal cancer who have already tried at least one other treatment. It aims to see if the drug combo can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older, with colorectal cancer that has spread to other organs.
- You need to be in reasonably good health (able to do daily activities without much trouble).
- You must have tried at least one previous treatment that didn't work or caused bad side effects.
- You need results from a genetic test that shows your tumor's gene type (like RAS/RAF mutations or MSI status).
- Your kidney, liver, heart, and blood counts must meet certain safety levels.
- You cannot have had certain drugs for this cancer before (like EGFR or MEK inhibitors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of drugs (envafolimab, cetuxima-β, and chemotherapy) for people with a specific type of advanced colorectal cancer that has not been treated yet. The goal is to see if it is safe and works well.
This trial tests if combining three targeted drugs (cetuximab, encorafenib, and binimetinib) before surgery can shrink or control cancer in people with a specific BRAF V600E mutation and a stable (MSS) tumor. It focuses on colorectal cancer that is either already able to be removed or could become removable with treatment.
This trial tests a combination of targeted therapies for people with metastatic colorectal cancer that has a specific BRAF V600E mutation and has progressed after initial treatment. The goal is to see if this combination can shrink tumors or stop them from growing further.
This trial tests a combination of targeted therapy (dabrafenib) and two other drugs (cetuximab or panitumumab) plus standard chemotherapy (FOLFOX) as a first treatment for people with a specific type of metastatic colorectal cancer that has a BRAF V600E mutation and is microsatellite stable.
This trial tests a combination of four drugs (irinotecan liposome, fluorouracil, folinic acid, vermofenib, and cetuximab) as a first treatment for people with advanced colorectal cancer that has a specific BRAF V600E mutation. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new CRC (Colorectal Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.